Last reviewed 2026-04-22 · How we verify

HCP1803-3

HCP1803-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.

HCP1803-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.

At a glance

Mechanism of action

The drug activates glucagon-like peptide-1 (GLP-1) receptors, which enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety. This mechanism reduces blood glucose levels and body weight in patients with type 2 diabetes and obesity-related conditions.

Approved indications

• Type 2 diabetes mellitus
• Obesity or weight management

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

Key clinical trials

• A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension (PHASE3)
• A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (PHASE3)
• A Study to Evaluate the PK, Safety and Tolerability of HCP1803. (PHASE1)
• A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HCP1803-3 CI brief — competitive landscape report
• HCP1803-3 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI